Repsol Spreads Footprint In Italy With First Renewable Project
Repsol SA (OTC:REPYY) announced renewable energy projects of around 1.77 gigawatts (GW) in Italy. The company plans to invest around €500…
One More Quits US Pharma Lobby Group: AstraZeneca Follows Teva, AbbVie Footsteps
AstraZeneca Plc (NASDAQ: AZN) has decided to leave a U.S. drug lobby group, the Pharmaceutical Research and Manufacturers of America (PhRMA), making it the third company to leave the group in the last six months.
Johnson & Johnson Sets Aside $400M To End US State Consumer Protection Claims
As a part of the $8.9 billion effort to settle claims related to talc products, Johnson & Johnson (NYSE:
FDA Signals Support For Pfizer’s Maternal RSV Shot Ahead Of Adcomm, Pfizer Raises $31B In Debt To Fund Seagen Deal
Pfizer Inc (NYSE: PFE) plans to raise $31 billion from a debt offering to finance its proposed acquisition of Seagen Inc (NASDAQ: SGEN)
AstraZeneca’ Tagrisso/Chemo Combo Therapy Delays Treatment Resistance, Disease Progression In Certain Type Of Advanced Lung Cancer
AstraZeneca Plc (NASDAQ: AZN) has reported topline data
Shell Collaborates With AI Technology Firm To Reduce Exploration Days: Report
Shell PLC (NYSE: SHEL) has reportedly collaborated with big-data analytics firm SparkCognition to use AI technology in deep-sea exploration.
Musk Addresses Tesla’s Profitability And Economic Challenges At Annual Shareholders’ Meeting
Elon Musk underscored Tesla Inc’s (NASDAQ:TSLA) profitability and forecasted a challenging economic environment in the upcoming year at…
What Is David Einhorn’s Greenlight Capital Trading? A Look At Its Q1 Portfolio
David Einhorn, founder and board chair of Greenlight Capital Re, Ltd (NASDAQ:GLRE) — and notorious critic of Tesla…
Value Investor Dan Loeb Bets Big On Tech, But Dumps Disney: Here Are His Top Picks
During the dot-com boom in the late 1990s to early 2000s, it seemed like any company that wanted…
FTC Files Lawsuit To Stop Amgen Buying Horizon Therapeutics, Sending Shockwaves Through Biopharma M&A
In a rare move to block a large pharma deal, the U.S.